NO322962B1 - Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens - Google Patents

Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens Download PDF

Info

Publication number: NO322962B1
Authority: NO; Norway
Prior art keywords: bssl; protein; amino acid; treatment; sequence
Prior art date: 1990-06-01

Application number

NO19924528A

Other languages

English (en)

Norwegian (no)

Other versions

NO924528D0 (no

NO924528L (no

Inventor

Gunnar Bjursell

Jeanette Nilsson

Lars Blackberg

Olle Hernell

Peter Carlsson

Sven Enerback

Thomas Olivecrona

Original Assignee

Arexis Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-01

Filing date

1992-11-24

Publication date

2006-12-18

1992-11-24 Application filed by Arexis Ab filed Critical Arexis Ab

1992-11-24 Publication of NO924528D0 publication Critical patent/NO924528D0/no

1992-11-24 Publication of NO924528L publication Critical patent/NO924528L/no

2006-12-18 Publication of NO322962B1 publication Critical patent/NO322962B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 12
102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 4
201000007089 exocrine pancreatic insufficiency Diseases 0.000 title claims description 4
239000000203 mixture Substances 0.000 title description 5
108090000623 proteins and genes Proteins 0.000 claims description 61
102000004169 proteins and genes Human genes 0.000 claims description 54
108090001060 Lipase Proteins 0.000 claims description 31
102000004882 Lipase Human genes 0.000 claims description 31
239000004367 Lipase Substances 0.000 claims description 31
235000019421 lipase Nutrition 0.000 claims description 31
238000004519 manufacturing process Methods 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 13
235000013343 vitamin Nutrition 0.000 claims description 8
239000011782 vitamin Substances 0.000 claims description 8
229940088594 vitamin Drugs 0.000 claims description 8
229930003231 vitamin Natural products 0.000 claims description 8
238000010521 absorption reaction Methods 0.000 claims description 7
201000003883 Cystic fibrosis Diseases 0.000 claims description 4
208000000668 Chronic Pancreatitis Diseases 0.000 claims description 3
206010033649 Pancreatitis chronic Diseases 0.000 claims description 3
230000001575 pathological effect Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims 5
235000018102 proteins Nutrition 0.000 description 50
102000004190 Enzymes Human genes 0.000 description 35
108090000790 Enzymes Proteins 0.000 description 35
229940088598 enzyme Drugs 0.000 description 35
125000003275 alpha amino acid group Chemical group 0.000 description 30
108010051152 Carboxylesterase Proteins 0.000 description 23
102000013392 Carboxylesterase Human genes 0.000 description 23
239000002299 complementary DNA Substances 0.000 description 22
108010058834 acylcarnitine hydrolase Proteins 0.000 description 21
108091028043 Nucleic acid sequence Proteins 0.000 description 18
229940040461 lipase Drugs 0.000 description 15
239000003833 bile salt Substances 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
125000003729 nucleotide group Chemical group 0.000 description 13
239000000047 product Substances 0.000 description 13
239000013598 vector Substances 0.000 description 12
230000001419 dependent effect Effects 0.000 description 10
210000005075 mammary gland Anatomy 0.000 description 10
229940093761 bile salts Drugs 0.000 description 9
235000020256 human milk Nutrition 0.000 description 8
210000004251 human milk Anatomy 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
238000000034 method Methods 0.000 description 8
239000000758 substrate Substances 0.000 description 8
241000283690 Bos taurus Species 0.000 description 7
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 7
108010087173 bile salt-stimulated lipase Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 7
235000013336 milk Nutrition 0.000 description 7
239000008267 milk Substances 0.000 description 7
210000004080 milk Anatomy 0.000 description 7
210000000496 pancreas Anatomy 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
108090000371 Esterases Proteins 0.000 description 6
206010025476 Malabsorption Diseases 0.000 description 6
208000004155 Malabsorption Syndromes Diseases 0.000 description 6
108090000631 Trypsin Proteins 0.000 description 6
102000004142 Trypsin Human genes 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000013595 glycosylation Effects 0.000 description 6
238000006206 glycosylation reaction Methods 0.000 description 6
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
239000012588 trypsin Substances 0.000 description 6
102100035687 Bile salt-activated lipase Human genes 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
230000029087 digestion Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
230000007017 scission Effects 0.000 description 5
241000894007 species Species 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
102100033639 Acetylcholinesterase Human genes 0.000 description 4
108010022752 Acetylcholinesterase Proteins 0.000 description 4
102100036045 Colipase Human genes 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
101000876022 Homo sapiens Colipase Proteins 0.000 description 4
239000007993 MOPS buffer Substances 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
210000000577 adipose tissue Anatomy 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
210000004293 human mammary gland Anatomy 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000009469 supplementation Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
-1 vitamin esters Chemical class 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
241000168726 Dictyostelium discoideum Species 0.000 description 3
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
101000715643 Homo sapiens Bile salt-activated lipase Proteins 0.000 description 3
102000019280 Pancreatic lipases Human genes 0.000 description 3
108050006759 Pancreatic lipases Proteins 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
102100033504 Thyroglobulin Human genes 0.000 description 3
108010034949 Thyroglobulin Proteins 0.000 description 3
229940022698 acetylcholinesterase Drugs 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
102000005311 colipase Human genes 0.000 description 3
108020002632 colipase Proteins 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
102000052905 human CEL Human genes 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
150000002759 monoacylglycerols Chemical class 0.000 description 3
229940116369 pancreatic lipase Drugs 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
229960002175 thyroglobulin Drugs 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000003914 Cholinesterases Human genes 0.000 description 2
108090000322 Cholinesterases Proteins 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102000004157 Hydrolases Human genes 0.000 description 2
108090000604 Hydrolases Proteins 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
229940048961 cholinesterase Drugs 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
150000001982 diacylglycerols Chemical class 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
235000012041 food component Nutrition 0.000 description 2
235000013350 formula milk Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
108010091264 gastric triacylglycerol lipase Proteins 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
229940015043 glyoxal Drugs 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000001630 jejunum Anatomy 0.000 description 2
230000002366 lipolytic effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
KRZWEBVPFGCYMY-UHFFFAOYSA-M methylmercury(1+);hydroxide Chemical compound [OH-].[Hg+]C KRZWEBVPFGCYMY-UHFFFAOYSA-M 0.000 description 2
239000000693 micelle Substances 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000537222 Betabaculovirus Species 0.000 description 1
102100036806 Carboxylesterase 5A Human genes 0.000 description 1
102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 1
108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
108700012227 Drosophila ase Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000800133 Homo sapiens Thyroglobulin Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
101710128782 Liver carboxylesterase Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102100037611 Lysophospholipase Human genes 0.000 description 1
108020002496 Lysophospholipase Proteins 0.000 description 1
102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
102000014171 Milk Proteins Human genes 0.000 description 1
108010011756 Milk Proteins Proteins 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000016222 Pancreatic disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
101000715641 Rattus norvegicus Bile salt-activated lipase Proteins 0.000 description 1
101100235661 Rattus norvegicus Lpl gene Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
108010055297 Sterol Esterase Proteins 0.000 description 1
102000000019 Sterol Esterase Human genes 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
241000251735 Torpedo marmorata Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
238000013103 analytical ultracentrifugation Methods 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000005417 food ingredient Substances 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
239000002628 heparin derivative Substances 0.000 description 1
102000047688 human TG Human genes 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000016507 interphase Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
230000020958 lipid digestion Effects 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
235000021239 milk protein Nutrition 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000004203 pancreatic function Effects 0.000 description 1
210000001819 pancreatic juice Anatomy 0.000 description 1
238000009928 pasteurization Methods 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
239000012071 phase Substances 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
235000020185 raw untreated milk Nutrition 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
108020002447 serine esterase Proteins 0.000 description 1
102000005428 serine esterase Human genes 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
125000003203 triacylglycerol group Chemical group 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Birds (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO19924528A 1990-06-01 1992-11-24 Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens NO322962B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9001985A SE9001985D0 (sv)	1990-06-01	1990-06-01	New chemical products
PCT/SE1991/000381 WO1991018923A1 (en)	1990-06-01	1991-05-30	Derivatives of human bile-salt stimulated lipase, and pharmaceutical compositions containing them

Publications (3)

Publication Number	Publication Date
NO924528D0 NO924528D0 (no)	1992-11-24
NO924528L NO924528L (no)	1992-11-24
NO322962B1 true NO322962B1 (no)	2006-12-18

Family

ID=20379662

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19924528A NO322962B1 (no)	1990-06-01	1992-11-24	Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens

Country Status (44)

Country	Link
EP (1)	EP0535048B1 (de)
JP (1)	JPH05507201A (de)
KR (1)	KR100212411B1 (de)
CN (2)	CN1075113C (de)
AP (1)	AP207A (de)
AT (1)	ATE151077T1 (de)
AU (1)	AU651979B2 (de)
BG (1)	BG61165B1 (de)
CA (1)	CA2083396C (de)
CZ (1)	CZ287470B6 (de)
DE (1)	DE69125489T2 (de)
DK (1)	DK0535048T3 (de)
DZ (1)	DZ1503A1 (de)
EG (1)	EG19937A (de)
ES (1)	ES2099159T3 (de)
FI (1)	FI114639B (de)
GR (1)	GR3023618T3 (de)
HK (1)	HK62497A (de)
HR (1)	HRP920771B1 (de)
HU (1)	HU215258B (de)
IE (1)	IE911844A1 (de)
IL (1)	IL98273A (de)
IS (1)	IS1751B (de)
JO (1)	JO1694B1 (de)
LT (1)	LT4020B (de)
LV (1)	LV10292B (de)
MA (1)	MA22166A1 (de)
MY (1)	MY111245A (de)
NO (1)	NO322962B1 (de)
NZ (1)	NZ238223A (de)
PH (1)	PH30761A (de)
PL (1)	PL166534B1 (de)
PT (1)	PT97836B (de)
RO (1)	RO114793B1 (de)
RU (1)	RU2140983C1 (de)
SE (1)	SE9001985D0 (de)
SG (1)	SG48078A1 (de)
SK (1)	SK281089B6 (de)
TN (1)	TNSN91041A1 (de)
TW (1)	TW221712B (de)
UA (1)	UA39165C2 (de)
WO (1)	WO1991018923A1 (de)
YU (1)	YU49138B (de)
ZA (1)	ZA913778B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5616483A (en) *	1992-06-11	1997-04-01	Aktiebolaget Astra	Genomic DNA sequences encoding human BSSL/CEL
IS4130A (is) *	1993-03-01	1994-09-02	Ab Astra	Ný fjölpeptíð
SE9300686D0 (sv)	1993-03-01	1993-03-01	Astra Ab	Novel polypeptides
FR2754827B1 (fr) *	1996-10-17	1998-12-24	Biocem	Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations
JP2000026311A (ja) *	1998-07-02	2000-01-25	Amano Pharmaceut Co Ltd	胃排出能亢進剤組成物
EP1963524A2 (de) *	2005-12-01	2008-09-03	University of Bergen	Diagnose und behandlung von exokriner pankreasfehlfunktion und diabetes unter verwendung des menschlichen cel-gens
MX338426B (es)	2010-04-23	2016-04-15	Synageva Biopharma Corp	Enzima de enfermedad del almacenamiento lisosomico.
DK2613798T4 (en)	2010-09-09	2018-04-16	Synageva Biopharma Corp	USING LYSOSOMAL SUR LIPASE TO TREAT PATIENTS WITHOUT LYSOSOMAL SUR LIPASE
CA2812852A1 (en)	2010-10-21	2012-04-26	Swedish Orphan Biovitrum Ab (Publ)	Method to increase the absorption of unsaturated fatty acids by human infants
DK2629790T3 (en) *	2010-10-21	2016-10-24	Swedish Orphan Biovitrum Ab (Publ)	Approach to increase growth rate of human babies
KR20200018781A (ko) *	2017-06-19	2020-02-20	스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘)	반감기 연장 폴리펩티드를 갖는 융합 단백질
MX2022002473A (es)	2019-08-30	2022-08-02	Codexis Inc	Variantes de lipasa modificadas geneticamente.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3107684A (en) *	1983-07-01	1985-02-07	Celltech Limited	Proteins, pharmaceutical compositions, genes, vectors, host organisms and processes for their production

1990
- 1990-06-01 SE SE9001985A patent/SE9001985D0/xx unknown
1991
- 1991-05-17 ZA ZA913778A patent/ZA913778B/xx unknown
- 1991-05-18 TW TW080103838A patent/TW221712B/zh not_active IP Right Cessation
- 1991-05-20 DZ DZ910064A patent/DZ1503A1/fr active
- 1991-05-22 NZ NZ238223A patent/NZ238223A/xx not_active IP Right Cessation
- 1991-05-23 MY MYPI91000877A patent/MY111245A/en unknown
- 1991-05-27 IL IL9827391A patent/IL98273A/xx not_active IP Right Cessation
- 1991-05-29 YU YU95191A patent/YU49138B/sh unknown
- 1991-05-29 MA MA22438A patent/MA22166A1/fr unknown
- 1991-05-29 EG EG33391A patent/EG19937A/xx active
- 1991-05-30 AT AT91911030T patent/ATE151077T1/de not_active IP Right Cessation
- 1991-05-30 PL PL91296937A patent/PL166534B1/pl unknown
- 1991-05-30 HU HU9203774A patent/HU215258B/hu unknown
- 1991-05-30 WO PCT/SE1991/000381 patent/WO1991018923A1/en not_active Ceased
- 1991-05-30 EP EP91911030A patent/EP0535048B1/de not_active Expired - Lifetime
- 1991-05-30 JP JP91510382A patent/JPH05507201A/ja active Pending
- 1991-05-30 SG SG1996006887A patent/SG48078A1/en unknown
- 1991-05-30 UA UA93003780A patent/UA39165C2/uk unknown
- 1991-05-30 RO RO92-01490A patent/RO114793B1/ro unknown
- 1991-05-30 RU RU92016526/13A patent/RU2140983C1/ru active
- 1991-05-30 DE DE69125489T patent/DE69125489T2/de not_active Expired - Lifetime
- 1991-05-30 DK DK91911030.4T patent/DK0535048T3/da active
- 1991-05-30 IE IE184491A patent/IE911844A1/en not_active IP Right Cessation
- 1991-05-30 AU AU79645/91A patent/AU651979B2/en not_active Expired
- 1991-05-30 CA CA002083396A patent/CA2083396C/en not_active Expired - Lifetime
- 1991-05-30 ES ES91911030T patent/ES2099159T3/es not_active Expired - Lifetime
- 1991-05-31 CZ CS19911644A patent/CZ287470B6/cs not_active IP Right Cessation
- 1991-05-31 IS IS3710A patent/IS1751B/is unknown
- 1991-05-31 SK SK1644-91A patent/SK281089B6/sk not_active IP Right Cessation
- 1991-05-31 PT PT97836A patent/PT97836B/pt not_active IP Right Cessation
- 1991-05-31 TN TNTNSN91041A patent/TNSN91041A1/fr unknown
- 1991-06-01 JO JO19911694A patent/JO1694B1/en active
- 1991-06-01 CN CN91104368A patent/CN1075113C/zh not_active Expired - Lifetime
- 1991-06-01 AP APAP/P/1991/000270A patent/AP207A/en active
- 1991-10-11 PH PH43285A patent/PH30761A/en unknown
1992
- 1992-10-01 HR HRP-951/91A patent/HRP920771B1/xx not_active IP Right Cessation
- 1992-11-24 NO NO19924528A patent/NO322962B1/no not_active IP Right Cessation
- 1992-11-26 BG BG97123A patent/BG61165B1/bg unknown
- 1992-11-30 FI FI925453A patent/FI114639B/fi active IP Right Grant
- 1992-11-30 KR KR1019920703049A patent/KR100212411B1/ko not_active Expired - Lifetime
1993
- 1993-07-30 LV LVP-93-1005A patent/LV10292B/en unknown
- 1993-12-30 LT LTIP1736A patent/LT4020B/lt not_active IP Right Cessation
1997
- 1997-05-08 HK HK62497A patent/HK62497A/en not_active IP Right Cessation
- 1997-05-30 GR GR970401262T patent/GR3023618T3/el unknown
2000
- 2000-11-20 CN CN00130975A patent/CN1326782A/zh active Pending

Also Published As

Publication number	Publication date
EP0535048B1 (de)	1997-04-02
HU215258B (hu)	1998-11-30
HRP920771B1 (en)	1999-10-31
AP9100270A0 (en)	1991-07-31
SK164491A3 (en)	1995-07-11
SE9001985D0 (sv)	1990-06-01
RO114793B1 (ro)	1999-07-30
GR3023618T3 (en)	1997-08-29
IL98273A0 (en)	1992-06-21
IL98273A (en)	2005-11-20
EP0535048A1 (de)	1993-04-07
NO924528D0 (no)	1992-11-24
CN1326782A (zh)	2001-12-19
HUT63184A (en)	1993-07-28
NZ238223A (en)	1993-05-26
JO1694B1 (en)	1992-08-09
FI925453L (fi)	1992-11-30
LTIP1736A (en)	1995-08-25
IE911844A1 (en)	1991-12-04
NO924528L (no)	1992-11-24
HRP920771A2 (en)	1997-04-30
DE69125489T2 (de)	1997-08-14
BG97123A (bg)	1993-12-24
HK62497A (en)	1997-05-16
CA2083396A1 (en)	1991-12-02
PT97836A (pt)	1992-02-28
CN1075113C (zh)	2001-11-21
CZ287470B6 (cs)	2000-12-13
DZ1503A1 (fr)	2004-09-13
FI925453A0 (fi)	1992-11-30
TNSN91041A1 (fr)	1992-10-25
KR100212411B1 (en)	1999-08-02
AU7964591A (en)	1991-12-31
ES2099159T3 (es)	1997-05-16
CZ164491A3 (cs)	1999-07-14
PT97836B (pt)	1998-11-30
BG61165B1 (bg)	1997-01-31
WO1991018923A1 (en)	1991-12-12
SK281089B6 (sk)	2000-11-07
TW221712B (de)	1994-03-11
ATE151077T1 (de)	1997-04-15
SG48078A1 (en)	1998-04-17
IS1751B (is)	2000-07-21
DK0535048T3 (da)	1997-09-29
UA39165C2 (uk)	2001-06-15
EG19937A (en)	2000-12-31
PL166534B1 (pl)	1995-05-31
RU2140983C1 (ru)	1999-11-10
CN1064313A (zh)	1992-09-09
JPH05507201A (ja)	1993-10-21
ZA913778B (en)	1992-02-26
CA2083396C (en)	2006-09-19
PH30761A (en)	1997-10-17
LV10292B (en)	1995-08-20
AP207A (en)	1992-08-18
YU49138B (sh)	2004-03-12
FI114639B (fi)	2004-11-30
AU651979B2 (en)	1994-08-11
MY111245A (en)	1999-10-30
HU9203774D0 (en)	1993-03-29
IS3710A7 (is)	1991-12-02
MA22166A1 (fr)	1991-12-31
DE69125489D1 (de)	1997-05-07
YU95191A (sh)	1994-06-10
LV10292A (lv)	1994-10-20
LT4020B (en)	1996-08-26

Legal Events

Date	Code	Title	Description
2011-06-14	MK1K	Patent expired

Publication	Publication Date	Title
Reue et al.	1991	cDNA cloning of carboxyl ester lipase from human pancreas reveals a unique proline-rich repeat unit.
Morimoto et al.	1989	Saposin A: second cerebrosidase activator protein.
Lowe et al.	1989	Cloning and characterization of human pancreatic lipase cDNA
McLean et al.	1986	Cloning and expression of human lecithin-cholesterol acyltransferase cDNA.
JP3072853B2 (ja)	2000-08-07	治療用に、組換方法で生産されたリパーゼ
AP207A (en)	1992-08-18	New DNA sequences and proteins coded for such DNA sequences.
ES2459217T3 (es)	2014-05-08	Producción enzimática de productos de lecitina hidrolizados
HU221119B1 (en)	2002-08-28	Variants of bile salt-stimulated lipase, dna molecules encoding them, and transgenic nonhuman mammals
JPH06315387A (ja)	1994-11-15	ポリペプチドとポリペプチド組成物
JP4933432B2 (ja)	2012-05-16	新規なリン脂質加工剤
JPS60501758A (ja)	1985-10-17	タンパク質、医薬構成物、遺伝子、ベクタ−宿主生物及びそれらの生産方法
Rice	1995	Secretory type II phospholipase A2 and the generation of intrauterine signals
KR102896630B1 (ko)	2025-12-08	식물성 알부민 및 이의 제조 방법
JP2004331565A (ja)	2004-11-25	皮膚コラーゲン産生促進剤
WO2001089553A1 (en)	2001-11-29	Enhanced triglyceride digestion in a deficiency of bile salts
US20020006655A1 (en)	2002-01-17	Purified proteolytic enzyme and method of purification
Timmermans	1996	Purification, mofecular cloning and expression of the cDNA of bovine pregastric esterase
JP2009027939A (ja)	2009-02-12	カルシウム結晶化阻害タンパク質
JP2000333688A (ja)	2000-12-05	改質油脂組成物の製造法